This Article Full Text Full Text (PDF) All Versions of this Article: 52/2/330    most recent HYPERTENSIONAHA.108.112029v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Höcherl, K. Articles by Bucher, M. Search for Related Content PubMed PubMed Citation Articles by Höcherl, K. Articles by Bucher, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Animal models of human disease Growth factors/cytokines CV surgery: aortic and vascular disease Lipid and lipoprotein metabolism Other Vascular biology

(Hypertension. 2008;52:330.)
© 2008 American Heart Association, Inc.

Original Articles

Activation of the PGI₂/IP System Contributes to the Development of Circulatory Failure in a Rat Model of Endotoxic Shock

Klaus Höcherl; Christoph Schmidt; Birgül Kurt; Michael Bucher

From the Institutes of Physiology (K.H.) and Anesthesiology (C.S., B.K., M.B.), University of Regensburg, Regensburg, Germany.

Correspondence to Klaus Höcherl, Universität Regensburg, Institut für Physiologie, Universitätsstr 31, D-93040 Regensburg, Germany. E-mail klaus.hoecherl{at}chemie.uni-regensburg.de

Prostacyclin levels are increased in septic patients and several animal models of septic shock, and selective inhibition of cyclooxygenase-2 improved cardiovascular dysfunction in rats treated with lipopolysaccharide (LPS). Here, we examine the specific role of prostacyclin and of the receptor for prostacyclin (IP) in the development of LPS-induced circulatory failure. Intravenous injection of LPS (10 mg/kg) into male Sprague-Dawley rats caused a strong increase in plasma prostacyclin levels, which was paralleled by a decrease in blood pressure and an increase in heart rate. Moreover, LPS injection increased the mRNA expression of the IP receptor in the heart, aorta, lung, liver, adrenal glands, and kidneys. Cotreatment with the IP antagonist CAY-10441 (1, 10, 30, and 100 mg/kg) dose-dependently moderated the LPS-induced changes in mean arterial blood pressure, heart rate, cardiac output, and systemic vascular resistance. The development of cardiovascular failure was ameliorated by CAY-10441 in spite of the typical LPS-induced increases in plasma levels of cytokines and NO. In vitro, cytokines dose- and time-dependently induced IP expression in rat vascular smooth muscle cells. Incubation of cells with the stable IP agonist iloprost in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-mehylxanthine resulted in higher cAMP levels in cytokine-treated cells compared with untreated cells. Taken together, our data demonstrate a prominent role of the prostacyclin/IP system in the development of LPS-induced cardiovascular failure.

Key Words: prostacyclin • LPS • CAY-10441 • blood pressure • sepsis